moxifloxacin has been researched along with dolasetron in 9 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (dolasetron) | Trials (dolasetron) | Recent Studies (post-2010) (dolasetron) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 191 | 89 | 14 |
| Protein | Taxonomy | moxifloxacin (IC50) | dolasetron (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 6.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benson, C; Brown, R; Couderc, JP; Darpo, B; Dota, C; Ferber, G; Ferry, J; Jarugula, V; Keirns, J; Ortemann-Renon, C; Pham, T; Riley, S; Sarapa, N; Ticktin, M; Zareba, W | 1 |
1 review(s) available for moxifloxacin and dolasetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and dolasetron
| Article | Year |
|---|---|
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
Topics: Arrhythmias, Cardiac; Biomarkers; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Indoles; Ion Channels; Long QT Syndrome; Male; Moxifloxacin; Ondansetron; Phenethylamines; Quinine; Quinolizines; Risk Assessment; Sulfonamides | 2020 |
7 other study(ies) available for moxifloxacin and dolasetron
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |